Filters

 

Resource Type
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm

Bradley J. Ridder, Derek J. Leishman, Matthew Bridgland-Taylor, Mohammadreza Samieegohar, Xiaomei Han, Wendy W. Wu, Aaron Randolph, Phu Tran, Jiansong Sheng, Timm Danker, Anders Lindqvist, Daniel Konrad, Simon Hebeisen, Liudmila Polonchuk, Evgenia Gissinger, Muthukrishnan Renganathan, Bryan Koci, Haiyang Wei, Jingsong Fan, Paul Levesque, Jae Kwagh, John Imredy, Jin Zhai, Marc Rogers, Edward Humphries, Robert Kirby, Sonja Stoelzle-Feix, Nina Brinkwirth, Maria Giustina Rotordam, Nadine Becker, Søren Friis, Markus Rapedius, Tom A. Goetze, Tim Strassmaier, George Okeyo, James Kramer, Yuri Kuryshev, Caiyun Wu, Herbert Himmel, Gary R. Mirams, David G. Strauss, Rémi Bardenet, Zhihua Lia. Toxicology and Applied Pharmacology, 394: 114961

Read More
Ion channel drug discovery and modern medicine

Rogers, M. MedNous, November-December 2019. Article published in the November-December 2019 edition of ‘MedNous’, a publication of Evernow Publishing Ltd.

Read More
The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients

Meents, J.E.; Bressan, E.; Sontag, S.; Foerster, A.; Hautvast, P.; Rösseler, C.; Hampl, M.; Schüler, H.; Goetzke, R.; Le TKC.; Kleggetveit, I.P.; Le Cann, K.; Kerth, C.; Rush, A.M.; Rogers, M.; Kohl, Z.; Schmelz, M.; Wagner, W.; Jørum, E.; Namer, B.; Winner, B.; Zenke, M.; Lampert, A. PAIN, March 22, 2019.

Read More
Recent advances in targeting ion channels to treat chronic pain

Stevens, E.B.; Stephens, G.J. British Journal of Pharmacology. 2018, 175 (12), 2133-2137

Read More
Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels

Zidar, N.; Žula, A.; Tomašič, T.; Rogers, M.; Kirby, RW.; Tytgat, J.; Peigneur, S.; Kikelj, D.; Ilaš, J.; Mašič LP. European Journal of Medicinal Chemistry. 2017, 139, 232-241

Read More
Characterization of endogenous sodium channels in the ND7-23 neuroblastoma cell line: implications for use as a heterologous ion channel expression system suitable for automated patch clamp screening

Rogers, M.; Zidar, N.; Kikelj, D.; Kirby, R.W. Assay and Drug Development Technologies. 2016, 14 (2),109-130

Read More
Novel K+ channel targets in atrial fibrillation drug development: where are we? 

El-Haou, S.; Ford, J.; Milnes, J. Journal of Cardiovascular Pharmacology. 2015, 66 (5), 412-431

Read More
Atrial‐like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial‐selective pharmacology 

Devalla, H.D.; Schwach, V.; Ford, J.W.; Milnes, J.T.; El‐Haou, S.; Jackson, C.; Gkatzis, K.; Elliott, D.A.; de Sousa Lopes, S.M.C.; Mummery, C.L.; Verkerk, A.O.; Passier, R. EMBO Molecular Medicine 2015. 7 (4), 394-410

Read More
Synthesis and biological evaluation of piperazine derivatives as novel isoform selective voltage-gated sodium (Nav) 1.3 channel modulators 

Jukič, M.; Frlan, R.; Chan, F.; Kirby, R.W.; Madge, D.J.; Tytgat, J.; Peigneur, S.; Anderluh, M.; Kikelj, D. Medicinal Chemistry Research. 2015, 24 (6), 2366-2380

Read More
Open access to the KCNQ channel: Retigabine and second generation M-current openers
Read More
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram